Wilson H. Miller

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations

Medicine, Oncology, Pharmacology +11

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.7K citations

Medicine, Oncology, Pharmacotherapy +16

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.6K citations · Full text

Medicine, Immunology, Oncology +17

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen et al. · New England Journal of Medicine · 2019 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +6